Othman Al-Sawaf, MD of University Hospital Cologne discusses fixed-duration venetoclax-obinutuzumab forpreviously untreated patients with CLL: follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.
Read here:Â https://meetinglibrary.asco.org/record/186845/abstract